Indacaterol | The First Once-daily Long-acting Beta2 Agonist for COPD | Alexandre Trifilieff | Buch | Milestones in Drug Therapy | HC runder Rücken kaschiert | VII | Englisch | 2013 | Springer Basel - edition reliée, livre de poche

Livre dans la base de données depuis 2014-09-14T18:56:16+02:00 (Zurich)
Page de détail modifiée en dernier sur 2023-12-18T12:29:41+01:00 (Zurich)
ISBN/EAN: 9783034807081

ISBN - Autres types d'écriture:
3-0348-0708-2, 978-3-0348-0708-1
Autres types d'écriture et termes associés:
Auteur du livre: alexandre, basel iii
Titre du livre: acting first six, copd, milestones

Données de l'éditeur

Auteur: Alexandre Trifilieff
Titre: Milestones in Drug Therapy; Indacaterol - The First Once-daily Long-acting Beta2 Agonist for COPD
Editeur: Springer; Springer Basel
146 Pages
Date de parution: 2013-11-27
Basel; CH
Imprimé / Fabriqué en
Poids: 3,613 kg
Langue: Anglais
106,99 € (DE)
109,99 € (AT)
118,00 CHF (CH)
POD
VII, 146 p. 41 illus., 21 illus. in color.

BB; Pharmacology/Toxicology; Hardcover, Softcover / Medizin/Pharmazie; Pharmakologie; Verstehen; Asthma; Beta-2-Agonists; Bronchitis; Bronchodilatator; Lung function; Pneumology/Respiratory System; Pharmacology; Pneumology; Lungen- und Bronchialheilkunde; EA

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.

This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

Current Pharmacotherapy for COPD.- The preclinical pharmacology of indacaterol.- The design of the indacaterol molecule.- The early clinical development of Indacaterol.- INHANCE: An adaptive confirmatory study with dose selection at interim.- Phase III clinical efficacy studies – lung function.- Phase III Clinical Efficacy of Indacaterol.- Patient-centered Outcomes.- The history and performance of the Breezhaler device.- What does the future hold for the therapy of COPD?  

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.

This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

Summarizes preclinical and clinical data

A valuable source of information for scientists and clinicians

Contemporary monograph on the pharmacotherapy of COPD

Includes supplementary material: sn.pub/extras